Showing results (141-150 of 288) with videos related to
Sort By:
Pageof 29
The Prostate|July 21, 2004
The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trialAli Ziada, Albaha Barqawi, L Michael Glode, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111Maha Hussain, Catherine M Tangen, Primo N Lara, et al.International Journal of Cancer|June 29, 2007
IGF-1 and IGFBP-3: Risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening TrialJocelyn M Weiss, Wen-Yi Huang, Sabina Rinaldi, et al.Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|January 7, 2016
Human feasibility study of fluorescence spectroscopy guided optical biopsy needle for prostate cancer diagnosisPriya N Werahera, Edward A Jasion, Yongjun Liu, et al.International Journal of Radiation Oncology, Biology, Physics|March 26, 2014
The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based studyChad G Rusthoven, Julie A Carlson, Timothy V Waxweiler, et al.The Prostate|January 24, 2008
The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretionsNatalie J Serkova, Eduard J Gamito, Richard H Jones, et al.The Canadian Journal of Urology|December 22, 2015
Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancerE David Crawford, Daniel P Petrylak, Celestia S Higano, et al.BJU International|November 17, 2005
Factors contributing to the racial differences in prostate cancer mortalityAshutosh Tewari, Wolfgang Horninger, Alexandre E Pelzer, et al.BJU International|November 17, 2009
Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III studyFritz H Schröder, Bertrand Tombal, Kurt Miller, et al.Scandinavian Journal of Urology|January 10, 2019
FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonistE David Crawford, B Tombal, T Keane, et al.Pageof 29